STOCK TITAN

ParkerVision (OTCQB: PRKR) supplement: 12.8M shares, options extended

(Neutral)
(Neutral)
Form Type
424B3

Rhea-AI Filing Summary

ParkerVision, Inc. supplements its April 19, 2019 prospectus to register 12,800,000 shares of Common Stock for resale by selling stockholders, consisting of up to 7,800,000 shares issuable on conversion of convertible promissory notes and 5,000,000 shares issuable upon exercise of a five-year warrant. The company will not receive proceeds from the resale; if the warrant is exercised for cash, the company would receive up to $800,000 to be used, if received, to fund patent enforcement actions and for general corporate purposes. The supplement also attaches a Form 8-K disclosing that the Compensation Committee approved an extension of the expiration dates of certain fully vested nonqualified stock options for the CEO and CFO from August 7, 2026 to August 7, 2029, which the company expects will result in a one-time non-cash share-based compensation charge of approximately $360,000.

Positive

  • None.

Negative

  • None.

Insights

Option term extension preserves intended incentive value but creates a non-cash charge.

The Compensation Committee extended the expiration dates of fully vested nonqualified options granted on August 7, 2019 for the CEO (2,660,000 options) and CFO (870,550 options) without changing exercise price, share counts, or vesting. The exercise price remains $0.171.

The company expects to recognize a one-time non-cash share-based compensation charge of approximately $360,000. This charge is an accounting expense tied to modification accounting; cash flows are unaffected by the extension. Subsequent filings will show the charge in reported results.

Registered shares 12,800,000 shares Prospectus Supplement dated April 27, 2026
Conversion-linked shares 7,800,000 shares Issuable upon conversion of convertible promissory notes
Warrant shares 5,000,000 shares Issuable upon exercise of a five-year warrant
Potential warrant proceeds <money>$800,000</money> Gross proceeds if warrant exercised for cash
CEO options 2,660,000 options Options granted August 7, 2019; expiration extended to August 7, 2029
CFO options 870,550 options Options granted August 7, 2019; expiration extended to August 7, 2029
Exercise price <money>$0.171</money> per share Strike price of modified options
Expected non-cash charge <money>$360,000</money> One-time share-based compensation charge for option modification
Prospectus Supplement regulatory
"This Prospectus Supplement relates to the prospectus dated April 19, 2019"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
selling stockholders financial
"resale by the selling stockholders listed in the Prospectus"
Selling stockholders are existing owners of a company's shares who are offering some or all of their holdings for sale, often as part of a public offering or secondary transaction. For investors this matters because such sales increase the number of shares available to buy, can signal how confident current owners are about future prospects, and may put short-term pressure on the stock price similar to more tickets being released for a popular event.
nonqualified stock options compensation
"modification of certain outstanding nonqualified stock options"
A nonqualified stock option is a company-issued right that lets an employee or contractor buy shares later at a preset price, like a coupon to purchase stock regardless of the market price. It matters to investors because when the option is used the recipient owes ordinary-income tax on the difference between market and preset price, which affects the holder’s financial decisions and can change the company’s share count and reported expenses.
share-based compensation charge accounting
"one-time non-cash share-based compensation charge of approximately $360,000"
Offering Type resale/secondary
Use of Proceeds Company will not receive proceeds from resales; if the warrant is exercised for cash, proceeds up to $800,000 would be used to fund patent enforcement actions and for working capital and general corporate purposes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What does ParkerVision's prospectus supplement register (PRKR)?

It registers 12,800,000 shares of Common Stock for resale by selling stockholders, including 7,800,000 shares tied to convertible notes and 5,000,000 shares tied to a five-year warrant.

Will ParkerVision receive proceeds from the registered resale (PRKR)?

The company will not receive proceeds from resales by the selling stockholders. If the warrant is exercised for cash, the company could receive up to $800,000 in gross proceeds to fund patent actions and working capital.

What option modifications did ParkerVision disclose on the attached Form 8-K?

The Compensation Committee extended expiration dates of fully vested nonqualified options for the CEO (2,660,000) and CFO (870,550) from August 7, 2026 to August 7, 2029 with no change to exercise price or share counts.

How will the option extension affect ParkerVision's financials (PRKR)?

The company expects a one-time non-cash share-based compensation charge of approximately $360,000 related to the modifications; this is an accounting expense and not a cash outlay tied to the extension itself.

What are the stated uses for proceeds if the warrant is exercised (PRKR)?

If exercised for cash, the company expects to use proceeds to fund patent enforcement actions and for other working capital and general corporate purposes, as stated in the supplement.

Filed pursuant to Rule 424(b)(3)

Registration No. 333-230888

 

PROSPECTUS SUPPLEMENT No. 85

(to Prospectus dated April 19, 2019)

 

PARKERVISION, INC.

12,800,000 Shares of Common Stock

 

This Prospectus Supplement relates to the prospectus dated April 19, 2019, as amended and supplemented from time to time (the “Prospectus”), which permits the resale by the selling stockholders listed in the Prospectus of up to 12,800,000 shares of our common stock, par value $0.01 per share (“Common Stock”), consisting of (i) up to 7,800,000 shares of Common Stock issuable upon conversion of, and for the payment of interest from time to time at our option for, convertible promissory notes and (ii) 5,000,000 shares of Common Stock issuable upon the exercise of a five-year warrant. 

 

We will not receive proceeds from the sale of the shares of Common Stock by the selling stockholders. To the extent the warrant is exercised for cash, we will receive up to an aggregate of $800,000 in gross proceeds. We expect to use proceeds received from the exercise of the warrant, if any, to fund our patent enforcement actions and for other working capital and general corporate purposes.

 

This Prospectus Supplement is being filed to update and supplement the information previously included in the Prospectus with the information contained in our Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 27, 2026.  Accordingly, we have attached the 8-K to this prospectus supplement.  You should read this prospectus supplement together with the prospectus, which is to be delivered with this prospectus supplement.

 

Any statement contained in the Prospectus shall be deemed to be modified or superseded to the extent that information in this Prospectus Supplement modifies or supersedes such statement.  Any statement that is modified or superseded shall not be deemed to constitute a part of the Prospectus except as modified or superseded by this Prospectus Supplement. 

 

This Prospectus Supplement should be read in conjunction with, and may not be delivered or utilized without, the Prospectus.

 

Our Common Stock is listed on the OTCQB Venture Capital Market under the ticker symbol “PRKR.”

 

Investing in our securities involves a high degree of risk. See Risk Factors beginning on page 5 of the Prospectus for a discussion of information that should be considered in connection with an investment in our securities.

 

Neither the SEC nor any such authority has approved or disapproved these securities or determined whether this Prospectus or Prospectus Supplement is truthful or complete. Any representation to the contrary is a criminal offense.

 

The date of this Prospectus Supplement is April 27, 2026.

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

______________

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported):April 22, 2026

 

PARKERVISION, INC.

(Exact Name of Registrant as Specified in Charter)

     

Florida

000-22904

59-2971472

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

 

   

4446-1A Hendricks Avenue Suite 354, Jacksonville, Florida

32207

(Address of Principal Executive Offices)

(Zip Code)

 

(904) 732-6100

(Registrant’s Telephone Number, Including Area Code)

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

   

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

   

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

   

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

Trading Symbol

Name of Each Exchange on Which Registered

None

 

 

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter.

 

Emerging growth company   ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

 

 

 

 

Item 5.02(e) Compensatory Arrangements of Certain Officers

 

On April 22, 2026, the Compensation Committee of the Board of Directors (“Committee”) of ParkerVision, Inc. (the “Company”), approved the modification of certain outstanding nonqualified stock options held by its Chief Executive Officer, Jeffrey Parker, and its Chief Financial Officer, Cynthia French, in order to extend the expiration date of the options from August 7, 2026 to August 7, 2029 to preserve the intended long-term incentive value of the awards.

 

The modified options include 2,660,000 options awarded to Mr. Parker and 870,550 options awarded to Ms. French on August 7, 2019, with an exercise price of $0.171 per share and an original term of seven years. The options were fully vested as of the modification date and the Company expects to record a one-time non-cash share-based compensation charge of approximately $360,000 in connection with the modification of these awards.

 

The extension of the expiration date is the only modification made to these awards, and no changes were made to the exercise price, the number of shares subject to the awards, vesting status or any other terms of the awards. No additional securities were issued in connection with the modification.

 

 

 Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit

Description

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

     

Dated: April 27, 2026

   
   

PARKERVISION, INC.

     
   

By /s/ Cynthia French

   

Cynthia French

   

Chief Financial Officer